Abstract: Objective Dapagliflozin is a new antidiabetic drug. Recent studies have shown that dapagliflozin can not only lower hypoglycemia risk,but also reduce blood pressure（BP）. However,apaucity of information exists on which dose that dapagliflozin could ameliorate BP,given the fact that variable dapagliflozin doses in different clinical trials were used. Methods Literature search was performed from Pubmed,Cochrane and EMBase to evaluate whether dapagliflozin monotherapy（at a starting dose of 5mg once daily）could lower BP. Results The changes of systolic BP（SBP）,hemoglobin A1c（HbA1c）,and body weight were recorded from 6randomized controlled trials（RCT）,and the changes of diastolic BP（DBP）were recorded from 5RCT. A total of 986 patients were included.Overall analysis revealed that SBP was 3.83 mm Hg lower in patients treated with dapagliflozin（n=497）than patients in placebo group（n=428）（95% CI-5.42to-2.25 mm Hg,P＜0.01）. Likewise,DBP was 1.99 mm Hg lower in patients treated with dapagliflozin（n=411）than patients in placebo group（n=341）（95% CI-2.79to-1.19 mm Hg,P＜0.01）. As compared with placebo（n=455）,dapagliflozin treatment（n=519）lead to a reduction of HbA1 cby 0.61%（95% CI-0.72%to-0.50%,P＜0.01）. Meanwhile,body weight in patients under dapagliflozin treatment（n=526）was reduced by 1.45kg（95% CI-2.06to-0.85,P＜0.01）as compared with patients in placebo group（n=460）. Conclusion Dapagliflozin monotherapy at starting doses can reduce blood glucose and body weight,as well as blood pressure as compared with placebo treatment.